First-line therapy with tyrosine kinase inhibitors (TKI) targeting the respective gene mutations is usually recommended for NSCLC with driver gene mutations such as the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), BRAF, and ROS1 genes. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.